Delveinsight Report

  Chronic Obstructive Pulmonary Disease is one of the most widespread and debilitating respiratory conditions worldwide, marked by persistent airflow obstruction and ongoing inflammation in the lungs. Despite decades of medical progress in disease management and symptom relief, no curative option currently exists. However, the landscape is beginning to shift as research momentum accelerates. Biopharmaceutical innovators and research institutions are investing heavily in the Chronic Obstructive Pulmonary Disease Pipeline , aiming to deliver therapies that go beyond symptom control and address the root causes of the disease. DelveInsight’s latest analysis highlights the surge of activity in this area and explores how these advances could reshape the future of respiratory care. Chronic Obstructive Pulmonary Disease is a multifaceted condition often triggered by prolonged exposure to harmful particles and gases, including tobacco smoke and environmental pollutants. Traditional Chronic...

  Available NASH Therapeutic Strategies Non-alcoholic steatohepatitis (NASH), a progressive liver condition, continues to be a serious global health issue due to its potential progression to cirrhosis and liver failure. At present, there is still no FDA-approved medicine for NASH , though certain lifestyle changes and off-label drugs such as pioglitazone and vitamin E are commonly used. By 2024, available NASH therapies remain mostly supportive, with a strong emphasis on weight reduction, managing blood sugar, and controlling lipid levels. This unmet need for effective options has accelerated nash liver disease drug development within both biotech and pharmaceutical sectors. Emerging Therapies: The Future of NASH Treatment A growing pipeline of investigational therapies shows significant potential, including fibrosis-targeting agents, FXR agonists, and drugs that modulate metabolism. Among the notable players in this field are Madrigal Pharmaceuticals and Akero Therapeutics, the l...

 Presbyopia is a natural part of aging in which the eyes gradually lose the ability to focus on close objects. The term “presbyopia” derives from a Greek phrase meaning “old eye.” Most people begin to notice its effects after the age of 40, as the lenses of the eyes gradually lose elasticity with age. Presbyopia can be categorized into several types: incipient, functional, absolute, premature, and nocturnal. The condition primarily results from age-related changes in the lens proteins, which cause the lens to become thicker, harder, and less flexible. Download the full infographic to uncover detailed insights: https://www.delveinsight.com/infographics/presbyopia-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr

Neurotrophic keratitis (NK) is a rare, degenerative disorder of the cornea that occurs when the trigeminal nerve is damaged, resulting in reduced or lost corneal sensation. This condition can lead to corneal ulcers, scarring, and potentially vision loss if left untreated. NK is commonly linked to diabetes, herpes zoster infection, or ocular trauma. Prompt diagnosis and early management are essential to prevent serious complications and protect vision. Download the full infographic to uncover detailed insights: https://www.delveinsight.com/infographics/neurotrophic-keratitis-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr  

Ankylosing Spondylitis (AS), also known as Bechterew's disease, is a common inflammatory rheumatic condition that primarily affects the axial skeleton. It typically causes inflammatory back pain, which can result in structural changes, functional limitations, and a reduced quality of life. AS often begins with a dull ache and stiffness in the lower back. Many individuals experience periods of intensified symptoms, or "flares," where pain and stiffness worsen for several weeks before subsiding. Download the full infographic to uncover detailed insights: https://www.delveinsight.com/infographics/axial-spondyloarthritis-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr  

  The treatment landscape for Polycythemia Vera (PV) in 2025 is evolving rapidly as new therapies, delayed generic launches, and shifting pricing strategies reshape the market. Jakafi Generics: Facing a Possible Delay? Jakafi, long established as a standard treatment for Polycythemia Vera, was expected to encounter generic competition following its patent expiration. However, recent signals indicate a potential delay in the availability of generics, allowing Incyte to extend its hold on the market. This directly affects the ongoing discussion of Jakafi vs Besremi , with prescribing decisions often hinging on cost differences and treatment convenience. Besremi Expands with Guideline Inclusion PharmaEssentia’s Besremi (ropeginterferon alfa-2b) has strengthened its position in the Polycythemia Vera space with inclusion in the National Comprehensive Cancer Network (NCCN) guidelines. Its long-acting profile offers a clear benefit compared to daily regimens. Still, concerns around Bes...